Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Caspofungin Acetate

FDA-approved product (powder, intravenous), marketed as Cancidas, Caspofungin Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Caspofungin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidemia
  • Candidiasis
  • Fungal infectious disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antimycotics for systemic use
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae57.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Caspofungin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Caspofungin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial

    NCT07788586 · start 2026-09

    Registered record
    Registry ID
    NCT07788586
    Conditions
    Candidemia; Invasive Candidiasis
    Interventions
    Caspofungin only within the study; Caspofungin for 3 days within the study; Placebo only within the study; Placebo for 4 days within the study
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2028-02
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia; Invasive Candidiasis
    InterventionCaspofungin only within the study; Caspofungin for 3 days within the study; Placebo only within the study; Placebo for 4 days within the study
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

    NCT05421858 · start 2024-12-11

    Registered record
    Registry ID
    NCT05421858
    Conditions
    Candidemia; Candidiasis, Invasive
    Interventions
    Fosmanogepix; Fosmanogepix; Caspofungin; Fluconazole; Placebo; Placebo; Placebo; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-12-11
    Completion
    2028-01-30
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia; Candidiasis, Invasive
    InterventionFosmanogepix; Fosmanogepix; Caspofungin; Fluconazole +4 more
    PhasePhase 3
    Registry statusRecruiting

  • A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

    NCT06194201 · start 2024-04-27

    Registered record
    Registry ID
    NCT06194201
    Conditions
    Patients With Candidemia and/or Invasive Candidiasis
    Interventions
    HRS9432; Caspofungin Acetate for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-04-27
    Completion
    2025-11-07
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Candidemia and/or Invasive Candidiasis
    InterventionHRS9432; Caspofungin Acetate for Injection
    PhasePhase 2
    Registry statusCompleted

  • Caspofungin for Pneumocystis Pneumonia in PLWHIV.

    NCT06691321 · start 2023-08-01

    Registered record
    Registry ID
    NCT06691321
    Conditions
    HIV-1-infection; Pneumocystis Pneumonia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-08-01
    Completion
    2025-09-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection; Pneumocystis Pneumonia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • PK/PD of Caspofungin in Children Severe Infection

    NCT04961593 · start 2022-10-01

    Registered record
    Registry ID
    NCT04961593
    Conditions
    Pharmacokinetics; Infection, Fungal
    Interventions
    Caspofungin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-10-01
    Completion
    2026-12-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics; Infection, Fungal
    InterventionCaspofungin
    PhaseNot recorded
    Registry statusRecruiting

  • Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics

    NCT06044558 · start 2022-09-01

    Registered record
    Registry ID
    NCT06044558
    Conditions
    Kidney Transplant Patients
    Interventions
    Combined with voriconazole; Combined with caspofungin; Tacrolimus-alone treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-09-01
    Completion
    2023-06-01
    Enrolment
    507

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant Patients
    InterventionCombined with voriconazole; Combined with caspofungin; Tacrolimus-alone treatment
    PhaseNot recorded
    Registry statusCompleted

  • A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

    NCT05178862 · start 2022-08-03

    Registered record
    Registry ID
    NCT05178862
    Conditions
    Candidiasis, Invasive; Candidemia
    Interventions
    SCY-078; Fluconazole; Echinocandin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-08-03
    Completion
    2025-12-16
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Invasive; Candidemia
    InterventionSCY-078; Fluconazole; Echinocandin
    PhasePhase 3
    Registry statusTerminated

  • PK/PD of the Sedatives, Analgesics and Antibiotics in Patients Receiving ECMO

    NCT03787550 · start 2020-02-07

    Registered record
    Registry ID
    NCT03787550
    Conditions
    Drug Effect
    Interventions
    The Sedatives, analgesics and antibiotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-02-07
    Completion
    2022-03-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Effect
    InterventionThe Sedatives, analgesics and antibiotics
    PhaseNot recorded
    Registry statusUnknown

  • Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis

    NCT03580733 · start 2019-01-01

    Registered record
    Registry ID
    NCT03580733
    Conditions
    ICU Yeast Intra-abdominal Infection
    Interventions
    caspofungin antifungal therapy; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-01-01
    Completion
    2024-12-04
    Enrolment
    448

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionICU Yeast Intra-abdominal Infection
    Interventioncaspofungin antifungal therapy; placebo
    PhasePhase 3
    Registry statusUnknown

  • Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients

    NCT04674657 · start 2018-09-03

    Registered record
    Registry ID
    NCT04674657
    Conditions
    Critical Illness; Extracorporeal Membrane Oxygenation Complication; Infection
    Interventions
    blood drug concentration
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-09-03
    Completion
    2021-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Extracorporeal Membrane Oxygenation Complication; Infection
    Interventionblood drug concentration
    PhaseNot recorded
    Registry statusUnknown

  • Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients

    NCT06137690 · start 2018-07-01

    Registered record
    Registry ID
    NCT06137690
    Conditions
    Invasive Fungal Infection
    Interventions
    other antifungal agents,breathing machine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-07-01
    Completion
    2024-03-01
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infection
    Interventionother antifungal agents,breathing machine
    PhaseNot recorded
    Registry statusUnknown

  • An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM

    NCT04004078 · start 2018-03-01

    Registered record
    Registry ID
    NCT04004078
    Conditions
    Invasive Fungal Infection
    Interventions
    other antifungal agents,breathing machine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-03-01
    Completion
    2021-05-01
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infection
    Interventionother antifungal agents,breathing machine
    PhaseNot recorded
    Registry statusCompleted

  • Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents

    NCT05881109 · start 2018-01-01

    Registered record
    Registry ID
    NCT05881109
    Conditions
    Invasive Fungal Infections
    Interventions
    Caspogunfin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-01-01
    Completion
    2019-03-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections
    InterventionCaspogunfin
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study)

    NCT02805049 · start 2017-01-28

    Registered record
    Registry ID
    NCT02805049
    Conditions
    Septic Shock; Peritonitis
    Interventions
    Echinocandins
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01-28
    Completion
    2018-06-18
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock; Peritonitis
    InterventionEchinocandins
    PhasePhase 4
    Registry statusCompleted

  • A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy

    NCT02895529 · start 2016-11-30

    Registered record
    Registry ID
    NCT02895529
    Conditions
    Hematologic Neoplasms
    Interventions
    Itraconazole; Caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2016-11-30
    Completion
    2018-05-02
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Neoplasms
    InterventionItraconazole; Caspofungin
    PhasePhase 4
    Registry statusTerminated